Viking obesity drug publication shows best-in-class potential
Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.






-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)


